Alpha 2.0
Login Register
» Authors » Matthew Lammi

Matthew Lammi

Explore the profile of Matthew Lammi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 289
Followers 0
Related Specialties
Pulmonary Medicine
Critical Care
General Medicine
Top 10 Co-Authors
Thenappan Thenappan
Sula Mazimba
Teresa De Marco
David Badesch
Oksana Shlobin
Jeffrey Sager
Murali Chakinala
James Klinger
Jeffrey S Sager
Daniel Grinnan
Published In
Am J Respir Crit Care Med
Lung
Pulm Circ
JAMA
J Scleroderma Relat Disord
Affiliations
Soon will be listed here.
Recent Articles
1.
Medication Non-Adherence in Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)
Robbins E, Bradley K, Badesch D, Burger C, Chybowski A, De Marco T, et al.
Ann Am Thorac Soc . 2025 Feb; PMID: 39965160
Pulmonary arterial hypertension (PAH) is associated with significant morbidity and mortality. The extent of medication non-adherence in PAH is uncertain and may be linked to adverse outcomes. There has been...
2.
Nephrogenic systemic fibrosis-related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy
Mansour J, Coleman C, Mendoza F, Lammi M, Saketkoo L
J Scleroderma Relat Disord . 2022 Oct; 7(3):NP7-NP11. PMID: 36211205
Nephrogenic systemic fibrosis typically occurs in patients with renal failure and is strongly associated with gadolinium exposure through stimulation of macrophage-activated fibrosis. Patients present with prominent fibrosis of the skin...
3.
HIV-associated Pulmonary Arterial Hypertension: A Report from the Pulmonary Hypertension Association Registry
Kolaitis N, Lammi M, Mazimba S, Feldman J, McConnell W, Sager J, et al.
Am J Respir Crit Care Med . 2022 Feb; 205(9):1121-1124. PMID: 35180043
No abstract available.
4.
Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry
Fakhri S, Hannon K, Moulden K, Peterson R, Hountras P, Bull T, et al.
Pulm Circ . 2020 Nov; 10(4):2045894020964342. PMID: 33240488
Background: WHO Group 1 pulmonary arterial hypertension is a progressive and potentially fatal disease. Individuals living at higher altitude are exposed to lower barometric pressure and hypobaric hypoxemia. This may...
5.
Prediction of Health-related Quality of Life and Hospitalization in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry
Min J, Badesch D, Chakinala M, Elwing J, Frantz R, Horn E, et al.
Am J Respir Crit Care Med . 2020 Nov; 203(6):761-764. PMID: 33211974
No abstract available.
6.
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
Self W, Semler M, Leither L, Casey J, Angus D, Brower R, et al.
JAMA . 2020 Nov; 324(21):2165-2176. PMID: 33165621
Importance: Data on the efficacy of hydroxychloroquine for the treatment of coronavirus disease 2019 (COVID-19) are needed. Objective: To determine whether hydroxychloroquine is an efficacious treatment for adults hospitalized with...
7.
Pulmonary tumor embolism
Lammi M, Wurzel J, Criner G
Lung . 2010 Jul; 188(5):441-3. PMID: 20607269
A 36-year-old woman with breast cancer was admitted with shortness of breath. A computed tomography angiogram was obtained and was negative for pulmonary embolism. She quickly developed hypoxemic respiratory failure...